Award
National Institute of General Medical Sciences 1R43GM150295-01A1
Topical treatment for burn pain by blocking cutaneous pain receptors.
Recipient
SERENTRIX, LLC
Award Amount
$340,685.00
Ceiling
$340,685.00
Awarded
July 23, 2024
Identifier
1R43GM150295-01A1
Development of a topical TRPV1 receptor antagonist, SER114, to treat burn pain by blocking specific pain receptors on the skin, building on prior clinical trial success.
Description
The project aims to develop a novel topically applied TRPV1 antagonist for burn pain treatment by targeting pain receptors on the skin. It leverages previous Phase 1 clinical trial success of SER114 for neuropathic pain and focuses on formulating SER114 for topical application to reduce burn pain.